Immunology

Amgen releases Humira biosimilar data

The company says ABP 510 hit its primary endpoint in an adalimumab comparison.

Merck scores first US PD-1 approval

Merck scores first US PD-1 approval

By By

The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have taken Bristol-Myers Squibb's Yervoy (ipilimumab).

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

BMS enters two immuno-oncology deals

The drugmaker has paired up with Incyte and CytomyX in two separate deals.

Takeda jumps into Humira space

Takeda jumps into Humira space

By

The FDA's approval of Takeda's Entyvio puts the drugmaker in the ulcerative colititis and Crohn's mix of prescription treatments.

Merck Q1 sales fall, but diabetes rises

Merck Q1 sales fall, but diabetes rises

By

Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.

Novartis expands immuno-oncology presence

Novartis expands immuno-oncology presence

By

The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Merck, Ablynx ink immunotherapy deal

The two will explore cancer-attacking nanobodies.

Analysts put weight on BMS in oncology

Analysts put weight on BMS in oncology

By

Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.

Drugmakers carve out immuno-oncology turf

Drugmakers carve out immuno-oncology turf

By

Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.

Takeda may be poised to expand IBS treatment category

By

Phase III results of its Crohn's and ulcerative colitis medication show positive patient response in a category among patients who have exhausted other options.

Email Newsletters

MM&M inVISION